Dr. Sabrina Arena on Innovative Preclinical Models in Advanced Prostate Cancer | IUCS 2025

Title: The INSIDE Study: Innovative Preclinical Models for Precision Medicine in Advanced Prostate Cancer 🗓️ Register for IUCS 2026: https://webplatform.planning.it/IUCS2... 👉 Visit https://oncoassist.com/ to streamline patient care with cutting-edge tools, guidelines, and calculators! 🎥 Oncology Bytes – IUCS 2025 | Featuring Sabrina Arena, PhD In this episode, Sabrina Arena, PhD, Associate Professor of Histology at the University of Torino,Dept of Oncology, presents preliminary findings from the INSIDE study, a prospective translational trial exploring innovative preclinical models for precision medicine in advanced prostate cancer. Despite therapeutic progress in prostate cancer, treatment resistance remains a major challenge. The INSIDE study aims to better understand DNA damage repair (DDR) alterations beyond BRCA and to generate patient-derived organoids that can be used for genomic and pharmacological profiling. 🧠 Key insights: The INSIDE study is a prospective trial focused on high-risk advanced prostate cancer and DDR gene mutations. As of March 2025, 68 patients had been enrolled in the study. The team developed a pipeline to generate patient-derived organoids (PC-PDOs) from tumor tissue. The study achieved a 77% organoid derivation success rate. 18% of organoids were suitable for pharmacological screening, highlighting the translational value of the model. Genomic profiling used whole-exome sequencing and TSO500-HRD to assess genomic variability and genomic instability scores. Preliminary results suggest DNA-PK, ATM, and ATR as promising pharmacological targets. The findings also suggest potential PARP inhibitor sensitivity beyond BRCA mutations, including selected homologous recombination gene variants. In the presentation, Dr. Arena also highlighted the practical feasibility of building a larger organoid biobank and using these models for molecular and drug-response profiling. These findings support the feasibility of integrating genomic and pharmacological data through organoid models to guide precision therapies in advanced prostate cancer, while expanding interest beyond BRCA toward a broader DDR landscape. 📄 Read the full abstract: https://urologycancersummit.org/iuc22... 🌐 Learn more at: https://oncoassist.com/ --------------------------------------------------- 📲 Oncology at your fingertips. Download the ONCOassist app: 📥 iOS & Android: https://sn85wy.short.gy/qxrruq 🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights! 🔔 Turn on notifications so you never miss an episode. 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin 📍 Twitter/X: https://bit.ly/oncoassisttwitter #OncologyBytes #IUCS2025 #ProstateCancer #PrecisionOncology #Organoids #DDR #TranslationalResearch #Oncoassist